Objective Increased left ventricular mass (LVM) and LV fibrosis mass (LVFM) are characteristics of hypertrophic cardiomyopathy (HCM). Additionally, a substantial increase in the plasma B-type natriuretic peptide (BNP) level is observed. Therefore, we investigated the interrelationship and clinical significances of these parameters in a HCM cohort that underwent cardiac MRI (CMR). Methods Patients with HCM (n=109) receiving regular outpatient treatment underwent CMR and follow-up through 2015 from CMR examinations. The clinical outcome measures were all-cause mortality, admission for worsening heart failure, and ventricular tachycardia/fibrillation. Results The baseline body mass index (BMI), LV outflow tract (LVOT) obstruction, New York Heart Association (NYHA) class, and increased left atrial dimension (LAD) index were associated with the plasma BNP level. In the CMR analysis, LVM and LVFM indices significantly correlated with the BNP level (r=0.422 and 0.368, respectively), which were independent determinants according to a multivariate analysis (p=0.009 and 0.023, respectively). A Kaplan-Meier analysis during a median follow-up of 19.4 months showed that the baseline LVM or LVFM index was not associated with the clinical outcomes. However, the baseline BNP level was significantly associated with them (p<0.001). In addition, a multivariate Cox proportional hazard analysis showed that plasma BNP was an independent predictor for the clinical outcomes after adjusting for age, sex, LVM, and LVFM. Conclusion The LVM and LVFM are determinants of the BNP level independent of the BMI, LVOT obstruction, LAD, and NYHA class in patients with HCM. However, plasma BNP may be a more sensitive integrated-marker for the clinical outcomes than LVM or LVFM.
Introduction
Heart failure (HF) and ventricular arrhythmia often complicate hypertrophic cardiomyopathy (HCM) and are associated with the patient's prognosis. HCM is characterized by abnormal hypertrophy of the left ventricle (LV), with markedly variable clinical manifestations and morphological and hemodynamic abnormalities (1, 2) . Myocyte hypertrophy, disarray, fibrosis, and microvascular dysfunction are the histopathological hallmarks of HCM. A recent study has suggested that an increased LV mass (LVM) measured using cardiac magnetic resonance (CMR) may be a predictive marker of the outcome (3) . In addition, myocardial fibrosis has been recently suggested to be a key mechanism for adverse outcomes (4, 5) . Chan et al. reported that extensive late gadolinium enhancement (LGE) measured by CMR provided additional information for assessing the sudden cardiac death (SCD) event risk among HCM patients during a median follow-up of 3.3 years (6) . In addition, a recent pooled analysis revealed that LGE imaging using CMR appears to have significant prognostic power in predicting the combined cardiovascular outcomes in HCM (7) . B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP), which are associated with the severity of HF and LV functions, are useful markers of the diagnosis, management, and prognosis in patients with HF (8) . Our previous studies have suggested that the BNP levels strongly reflect increased LV diastolic wall stress in patients with a broad spectrum of HF (9) . However, many other factors such as age, gender, renal function, and genetics are also known to affect the plasma BNP levels. In patients with HCM, BNP levels are substantially increased irrespective of HF, suggesting a different regulatory mechanism from other cardiomyopathies. The precise mechanism and determinants of BNP elevation in HCM patients remains unclear (10) . Nevertheless, a recent study has suggested that BNP is an independent predictor of morbidity and mortality, and the benefit of BNP measurement for the clinical evaluation and prognostication is incremental (11) .
Accordingly, we conducted the present study to clarify the relationship between the plasma BNP concentrations and possible determinants, including LV geometric, functional, and clinical factors, in patients with HCM. In particular, we performed an analysis of LVM and LV fibrosis mass (LVFM) quantifications using CMR to clarify their precise contribution to both the regulation of plasma BNP and clinical outcomes, including all-cause mortality and HF in this setting.
Materials and Methods

Study protocol
A total of 116 consecutive outpatients with HCM referred for CMR were enrolled between February 2010 and February 2015 at the Kinki University Hospital. The diagnosis of HCM in all patients was made according to the conventional criteria: LV hypertrophy ! 15 mm and asymmetric/focal on two-dimensional echocardiography in the absence of another disease that could account for this hypertrophy. The workup at the initial diagnosis included an electrocardiogram (ECG), echocardiography, and 24-h Holter ECG. An LV outflow tract (LVOT) obstruction was defined as an LVOT pressure gradient ! 30 mmHg at rest on echocardiography (12) . The left atrial dimension (LAD) and degree of mitral regurgitation (MR) were also assessed. MR was considered to be significant if at least grades 2-3 of 4 possible. The plasma BNP and serum creatinine (Cr) levels were obtained for clinical purposes at the time of evaluation. The plasma BNP level was measured using a fluorescence immunoassay (LSI Medience Corporation, Japan). The estimated glomerular filtration rate (eGFR) was calculated using the GFR equation for the Japanese population: GFR =194×(serum Cr) -1.094 × (age) -0.287 ×(0.739, if female). The present study was approved by the Institutional Review Board.
CMR image acquisition
CMR was performed using a 1.5-T scanner (Intera 1.5T, Philips Medical Systems, Amsterdam, The Netherlands) according to a standardized protocol. Cine images were acquired with a steady-state free-precession breath-hold sequence in three long-axis planes and contiguous short-axis slices (10 mm, no gap) from the atrioventricular ring to the apex. LGE images were obtained 10-15 minutes after an intravenous administration of 0.2 mmol/kg gadolinium-DTPA using an inversion recovery gradient echo sequence with 5mm slice thickness at the same position as the long-and short-axis cines at end-diastole (13) . The inversion time was adjusted per patient to an optimally null signal from a normal myocardium, typically between 250 and 350 ms.
Image analysis
The LV volume, LVM, and wall thickness were calculated with commercially available workstations (Aze Virtual Place, Aze, Tokyo, Japan). To calculate the LVM, the endocardial and epicardial borders of the LV myocardium were manually planimetered on successive short-axis cine images at end-diastole. Particular care was taken to avoid the inclusion of papillary muscles in the LVM calculation. The LVM was derived by the summation of the disks method and multiplication of the myocardial muscle volume by 1.05 g/cm 3 (13) . To assess the LGE, all short-axis slices from the base to the apex were visually inspected to identify areas of a normal (completely nulled) myocardium. The mean signal intensity [and standard deviation (SD)] was derived, and a threshold of 6 SD exceeding the mean was used to define the areas of LGE (14) . Summing the planimetered areas of LGE in all short-axis slices yielded the total volume (LVFM: g), which was also expressed as a proportion of the total LV myocardium (%LGE). All analyses were performed by an experienced reader and reviewed and confirmed by a second expert reader, with both independent observers blinded to patient identities and clinical profiles. Any discrepancies in the analysis between both readers were then adjudicated by a senior observer.
Clinical follow-up
The long-term clinical follow-up, through 50 months from CMR testing, was accomplished through a questionnaire completed by the patient, telephone interview, or a chart view. The combined clinical outcome measures were allcause mortality, admission for worsening HF, and sustained ventricular tachycardia/fibrillation, including appropriate implantable cardioverter-defibrillator (ICD) discharge. All events were based on the clinical diagnosis; however, to validate these events, the medical records were reviewed by us or the physician in charge.
Statistical analysis
The groups were compared using the χ 2 test for proportions and an unpaired t-test or analysis of variance for con- tinuous variables, as appropriate. A linear regression analysis was used to assess the linearity of the relationship between two variables, and Pearson's correlation coefficient was calculated. Furthermore, a multiple logistic regression analysis was used to adjust for the age, gender, and presence of other significant factors using the JMP version 10.0 software program. Event-free survival curves were analyzed using the Kaplan-Meier method and a comparison between the curves was carried out using the log-rank test. A multivariate analysis of the clinical outcomes was evaluated with Cox's proportional hazard model. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated. A value of p<0.05 was considered to be statistically significant. Results are expressed as the mean ± standard deviation (SD).
Results
Patient characteristics
A total of 116 consecutive patients diagnosed with HCM were enrolled in the present study. All the patients were able to complete the CMR examination. However, three and four patients were excluded due to a history of myocardial infarction and missing BNP data, respectively. The remaining 109 patients were analyzed in the present study. Table 1 shows the baseline clinical characteristics of the study population according to the tertiles of the plasma BNP level (tertile: low ! 96, 96< middle ! 228, 228 pg/mL < high). In a comparison among the BNP tertiles, increased BNP levels were associated with a higher prevalence in women, a decreased body mass index (BMI), higher New York Heart Association (NYHA) class, history of admission due to HF, and increased LAD index (all p<0.05). Patients with higher BNP tertiles were more likely to be taking diuretics or antiarrhythmic drugs. A univariate analysis showed that the presence of LVOT obstruction or an increased LAD index in addition to the BMI and NYHA class was a significant determinant of the plasma BNP levels ( Fig. 1A-D) .
CMR findings
No significant differences were observed in the LV enddiastolic index, end-systolic volume index, or ejection fraction among the tertiles of BNP levels (Table 2 ). However, the LV wall thickness and LVM index had significant associations with the BNP levels. Although no significant difference was observed in %LGE volume, the LVFM index showed an increasing trend toward according to the BNP tertile (p=0.067). Fig. 1E and F show that both the LVM and LVFM indices significantly correlated with the BNP level in scatter plots (r=0.422 and r=0.367, respectively). In addition, both indices were associated with a history of admission due to HF (p=0.011 and p=0.002, respectively) and NYHA class " II (p=0.020 and p=0.004, respectively).
Multivariate analysis for determinants of the BNP levels
A multivariable regression analysis revealed that the levels of LVM and LVFM indices were both independent determinants of the BNP concentrations after adjusting for age and gender (p=0.002 and p=0.034, respectively). The fit (R 2 ) of the model was 0.285. In addition, LVOT obstruction, BMI, and LAD index were independently associated with the BNP level ( Table 3 ). The R 2 of the model with the addition of these variables was 0.494.
Clinical outcome
During a median follow-up of 19.4 months (lower quartile, 7.6 months; upper quartile, 28.2 months), three patients died and eight patients were hospitalized for worsening HF. Three patients received appropriate ICD shock. The Kaplan-Meier analysis showed that the baseline LVM index (tertile: low ! 77.7, 77.7< middle ! 98.5, 98.5 g/m 2 < high) and LVFM index (tertile: low ! 6.0, 6.0< middle ! 17.5, 17.5 g/m 2 < high) were not associated with the clinical outcomes ( Fig. 2A and B) . A low tertile of the baseline BMI (! 21.0 kg/m 2 ) showed a trend toward a worse event-free survival (Fig. 2C) . In addition, a high tertile of the baseline LAD index (tertile: low ! 24.3, 24.3< middle ! 28.1, 28.1 mm/m 2 < high) was associated with a worse event-free survival (Fig. 2D ). Furthermore, the tertile of baseline BNP levels was significantly associated with the clinical outcomes (p<0.001) ( Fig. 2E) . In a multivariate Cox proportional hazard analysis, including age, gender, LVM index tertile, and LVFM index tertile, the BNP tertile was independently associated with the combined clinical outcome (p<0.001) ( Table 4 ).
Discussion
Relationship of BNP with LVM or LVF in HF
Currently, both BNP and NT-proBNP are widely used as markers for a variety of cardiovascular diseases, particularly as ideal markers of HF (15) . We previously demonstrated an excellent correlation between BNP and LV end-diastolic wall stress (EDWS) (R 2 =0.89, p<0.001) in patients with HF with a variety of etiologies (9) . However, patients with HCM were excluded in the analysis because the estimation of wall stress and LVM using echocardiography was difficult due to its heterogeneous hypertrophy. In addition, previ-ous studies suggested that not only myocytes, but also cardiac fibroblasts and infiltrating cells produce BNP in the myocardium (16, 17) . Therefore, we analyzed the determinants of plasma BNP levels using CMR, which currently offers a highly accurate and reproducible quantitative assessment of the LVM and LVFM (3) . As a result, both LVM and LVFM indices were shown to be associated with the BNP level in patients with HCM using correlation and multivariate analyses. Kahveci et al. previously reported the determinants of NT-proBNP levels in patients with HCM using echocardiography (18) . Using a multiple linear regression analysis, the LAD index and LV maximal wall thickness (MWT) were found to be independent predictors of an elevated NT-proBNP level. Although a similar result was obtained regarding the LAD index, the MWT did not correlate with the BNP level in the present study (p=0.0662). Instead, the LVM index was highly associated with the BNP level, consistent with a high accuracy of the LVM measurement using the CMR analysis. Increased LAD reflects an elevated left atrial pressure and a cumulative effect of LV filling pressure over time (19) . Although we did not estimate EDWS in the present study, a robust association between the LAD index and BNP suggests an important contribution of EDWS to the BNP level in patients with HCM (9) . Recently, Park et al. reported that the degree and distribution of LV hypertrophy was a determining factor of the NT-proBNP level using CMR in 103 patients with HCM (10). They showed a significant correlation between NT-proBNP and LVM or LGE to a similar extent. However, they showed that the extent of LGE was not an independent determinant using a multivariate analysis, which was discordant with our present findings. A significant correlation between the fibrosis severity and BNP level may reflect a contribution of the diastolic dysfunction or an increase in BNP production in non-myocyte cells in HCM, although the reason for the discordance is unclear.
Comparison to other cardiomyopathies
Our previous study included patients with HF of various etiologies, i.e., dilated cardiomyopathy, valvular heart disease, hypertensive heart disease, and ischemic cardiomyopathy/old myocardial infarction (9) . No significant association was observed between the LVM index using echocardiography and the BNP levels. Similar findings were also reported by Tasevska-Dinevska et al. (20) . This may be related to the fact that an increase in LVM compensates for increased EDWS relevant to HF. A strong association between BNP and the LVM index, as shown in the present study, may be a distinctive feature of HCM regardless of HF. However, in the general population, hypertensive subjects, and patients on hemodialysis, a significant correlation between LVM and the BNP level has been reported, which is likely due to the low prevalence of increased DWS in these subjects (21) .
Prognostic markers of HCM
Two recent studies in large cohorts of patients with HCM reported the relationship of BNP with the prognosis. BNP or NT-proBNP was associated with all-cause mortality and a subsequent need for septal reduction therapy or HF-related death and transplantation, respectively (11, 22) . We did not show the survival analysis regarding all-cause mortality because there were only three death events (mortality rate of 2.17 per 100 person-year, which was similar to their study). However, their baseline BNP level was high (885±886 pg/ mL vs. 229±263 pg/mL in 106 survivors), suggesting the possibility of using the BNP level as an all-cause mortality marker. In addition, in the present study, the BNP level was associated with the NYHA class and history of admission due to HF. Our present study, wherein two HF-related deaths and eight admissions for worsening HF in all 14 events were observed during a 1.6-year follow-up, also suggested that BNP elevation was a significant predictor of HFrelated events. Although baseline BNP is substantially increased regardless of HF, the BNP level may reflect clinical manifestations and predict future events in terms of HF in patients with HCM.
The BNP level was negatively associated with the BMI in this HCM cohort, which was concordant with the previous reports including ours (23) . In addition, in our study, the lowest tertile of baseline BMI (! 21.0 kg/m 2 ) showed a trend toward a worse event-free survival as shown in Fig. 2C . This may also be consistent with the previous observations that the risk for total mortality, CV mortality and hospitalization was highest in patients with chronic HF who were underweight as defined by a low BMI (24) . Thus, the lowest tertile of the BMI group showed an elevated BNP level, which might be associated, at least in part, with the finding that a higher BNP level was an independent predictor for the clinical outcomes.
Chan et al. reported the prognostic significance of myocardial fibrosis in 1,293 patients with HCM (6) . The presence and severity of fibrosis remained significant predictors of the combined cardiovascular outcomes, in particular the HF outcome after a multivariate analysis, which was also supported by a pooled analysis (7) . Fibrosis may be associated with systolic and diastolic dysfunction or ventricular arrhythmias, leading to mortality and HF outcome. In addition, Olivotto et al. showed that a markedly increased LVM index was a predictive marker of the outcome during a 2.6year follow-up (3). In the present study, the baseline LVM or LVFM index was not associated with the clinical outcomes, including all-cause mortality and HF admission, and the reasons for this discrepancy remain unknown. However, it may be due to the small number of mortality events, relatively short follow-up period, or pathophysiological differences such as the prevalence of fibrosis or extent of LV hypertrophy in the studied population. A recent meta-analysis suggested that the presence of LGE was significantly associated with SCD risk, cardiac mortality and all-cause mortality in patients with non-high-risk HCM and that the extent of LGE was not significantly related to the risk of SCD (25) . The HCM cohort in the present study may not be representative of the general HCM population, but rather a group with more advanced disease, which may affect the negative findings regarding the relationship between the LVFM and the clinical outcomes. Nonetheless, our present results suggest that the BNP level has a significant value as an integrated biomarker reflecting several cardiovascular risk factors as shown in the present study (aging, BMI, LVOT obstruction, LAD, LVM, and LVFM). Other factors relevant to the BNP levels, such as renal function, EDWS, and diastolic function, may contribute to the prognosis (9, 26, 27) . Furthermore, the plasma BNP level may be more sensitive than the LVM or LVFM for the prognosis in the HCM cohort.
Study limitations
There are several limitations associated with the present study. First, the study population was relatively small. Therefore, any negative findings could be caused by a low statistical power, particularly in the relationship between the LVM or LVFM and clinical outcomes. Second, the present study was a single-centered study; thus, it had several inherent limitations, including selection and referral biases. Our institution is a referral hospital and the HCM cohort in the present study may not be representative of the general HCM population, but rather a group with more advanced disease. Third, we assessed the BNP level only with CMR testing. The BNP levels typically show substantial variations and the serial measurements may have provided additional information (28) . Lastly, the study population consisted of HCM patients who could undergo CMR; patients who could not tolerate the procedure or would be at a high risk were excluded. In particular, patients with severe renal dysfunction (eGFR <30 mL/min/1.73 m 2 or on hemodialysis) were excluded and thus the relationship between BNP and renal function may be underestimated (27) .
Conclusion
In 109 consecutive HCM outpatients with CMR, both the LVM and LVFM indices in addition to the BMI, LVOT obstruction, LAD index, and NYHA class were independent determinants of the plasma BNP level. The Kaplan-Meier analysis during a median follow-up of 19.4 months revealed that the baseline BNP level, but not the LVM or LVFM index, was markedly associated with the clinical outcomes. Although the LVM or LVFM index alone was not a significant prognostic marker, the plasma BNP level as an integrated marker had a more sensitive prognostic value in this cohort of patients with HCM.
